Table 3.
Association of tRNA-GlyGCC-5 expression, sRESE expression and bi-sesncRNAs signature RSP with demographic and clinicopathological characteristics of the CHSUMC cohort
| Variables | Patients: n | tRNA-GlyGCC-5 level | P value | sRESE level | P value | Bi-sesncRNA signature | P value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Low: n (%) | High: n (%) | Low: n (%) | High: n (%) | Low: n (%) | High: n (%) | |||||
| Total samples | 200 | 100 (50.0) | 100 (50.0) | 100 (50.0) | 100 (50.0) | 100 (50.0) | 100 (50.0) | |||
| Age (years) | 200 | 59.99 ± 8.73 | 62.13 ± 9.28 | 0.095B | 60.58 ± 8.67 | 61.54 ± 9.44 | 0.455B | 60.19 ± 8.57 | 61.93 ± 9.47 | 0.175B |
| Gender | ||||||||||
| Female | 74 | 32 (43.2) | 42 (56.8) | 0.094A | 33 (44.6) | 41 (55.4) | 0.153A | 34 (45.9) | 40 (54.1) | 0.232 A |
| Male | 126 | 68 (54.0) | 58 (46.0) | 67 (53.2) | 59 (46.8) | 66 (52.4) | 60 (47.6) | |||
| Tumor depth | ||||||||||
| T1/T2 | 58 | 32 (55.2) | 26 (44.8) | 0.218A | 37 (63.8) | 21 (36.2) | 0.009A | 31 (53.4) | 27 (46.6) | 0.320A |
| T3/T4 | 142 | 68 (47.9) | 74 (52.1) | 63 (44.1) | 79 (55.6) | 69 (48.6) | 73 (51.4) | |||
| Lymph node metastasis | ||||||||||
| Negative | 85 | 54 (63.5) | 31 (36.5) | 0.001A | 55 (64.7) | 30 (35.3) | < 0.001A | 52 (61.2) | 33 (38.8) | 0.005A |
| Positive | 115 | 46 (40.0) | 69 (60.0) | 45 (39.1) | 70 (60.9) | 48 (41.7) | 67 (58.3) | |||
| Histological differentiation | ||||||||||
| Well | 60 | 40 (66.7) | 20 (33.3) | 0.007A | 39 (65.0) | 21 (35.0) | 0.012A | 43 (71.7) | 17 (28.3) | < 0.001A |
| Moderate | 99 | 44 (44.4) | 55 (55.6) | 46 (46.5) | 53 (53.5) | 41 (41.4) | 58 (58.6) | |||
| Poor | 41 | 16 (39.0) | 25 (61.0) | 15 (36.6) | 26 (63.4) | 16 (39.0) | 25 (61.0) | |||
| Largest tumor dimension (cm) | 200 | 4.70 ± 1.64 | 5.01 ± 1.22 | 0.135B | 4.82 ± 1.56 | 5.10 ± 1.60 | 0.217B | 4.84 ± 1.69 | 5.09 ± 1.45 | 0.256B |
| Stage | ||||||||||
| I/II | 78 | 47 (60.3) | 31 (39.7) | 0.029A | 47 (60.3) | 31 (39.7) | 0.029A | 43 (55.1) | 35 (44.9) | 0.310A |
| III | 122 | 53 (43.4) | 69 (56.6) | 53 (43.4) | 69 (56.6) | 57 (46.7) | 65 (53.3) | |||
High in this analysis is based on a salivary exosomal sesncRNA level or RSP higher than median; the remaining individuals were classified as low
Aχ2 test was used for comparing control and patient group
BUnpaired t test was used for comparing control and patient group